MedTrace Logo

Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

NCT05482464 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-04-04

No results posted yet for this study

Summary

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

Conditions

  • Inflammatory Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Casein glycomacropeptide (CGMP)

Casein glycomacropeptide (CGMP) supplementation for 3 weeks

Sponsors & Collaborators

  • BUILD Dairy

    collaborator UNKNOWN

  • Agropur

    collaborator UNKNOWN

  • Oregon State University

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-09-01
Completion
2024-09-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05482464 on ClinicalTrials.gov